Study S001762

Conditions for Prescribing Liraglutide in Medical Practice and Assessment of Maintenance Level, Tolerability, and Efficacy of Victoza® (Liraglutide) in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01226966
Acronym: EVIDENCE
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 3152
Start: 2010-09
Primary completion: 2013-11
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1116-2722

Registered primary outcomes

Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0% [Month 24]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025814	Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study. Martinez L, Advances in therapy	2017	Nonrandomized study	PMID 28138803 DOI	cites ClinicalTrials.gov:NCT01226966; registry reference RESULT:28138803
R0026114	Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study. Gautier JF, Advances in therapy	2015	Randomized trial	PMID 26424330 DOI	cites ClinicalTrials.gov:NCT01226966; registry reference RESULT:26424330